We aim to have near-term impact in the world by developing groundbreaking bioinspired technologies, ranging from novel devices and materials to high-value therapeutics and diagnostics, that are translated into commercial products and solutions. If you are interested in any of these technologies, please contact us.
Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.
Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized.
This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute.
Nearly 60% of greenhouse gas emissions are linked to the production and processing of meat. Using Wyss-developed technology, an alternative meat can be made from vegetable protein that has the same taste and texture as animal products.
PhonoGraft is an easy-to-use, biomimetic device that stimulates a patient's eardrum to heal itself after perforation. This regenerative medicine approach can enable better and longer-lasting eardrum reconstruction, reducing the need for invasive surgeries and minimizing the risk of long-term hearing loss.